Abstracts

NAFLD AND ITS COMBINATION WITH NASH PREDICT DM DEVELOPMENT IN PEOPLE WITH HIV

Background: We investigated the association of non-alcoholic fatty liver disease (NAFLD) plus or minus a concurrent diagnosis of non-alcoholic steato-hepatitis (NASH) with incident diabetes mellitus (DM) among Thai people living with HIV (PLWH). Methods: This prospective study analysed PLWH aged ≥18 years, on stable antiretroviral therapy (ART), in a long-term cohort in Bangkok, Thailand. Liver…

PREVALENCE AND FACTORS ASSOCIATED WITH NAFLD IN PEOPLE WITH HIV

Background: Non-alcoholic fatty liver disease (NAFLD) in people living with HIV (PLHIV) may be more common than in the general population. Screening recommendations for NAFLD in PLHIV are based on guidelines for the general population, not considering HIV-specific factors contributing to NAFLD. In this study, we assessed the prevalence of liver steatosis and fibrosis in…

PREDICTORS OF POST SWITCH VIREMIA IN PATIENTS ON INJECTABLE CABOTEGRAVIR/RILPIVIRINE

Background: Data are lacking evaluating predictors of varying levels of on-treatment elevations in viral load in patients receiving long-acting cabotegravir plus rilpivirine (CAB/RPV) for people with HIV (PWH). Study objectives were to I) quantify the occurrence of detectable viremia on CAB/RPV and II) determine if HIVRNA values in the preceding year predicted virologic outcomes. Methods:…

PROJECTED BENEFITS OF LONG-ACTING ART IN PWH WITH VIREMIA DESPITE PRESCRIBED ORAL ART

Background: Long-acting injectable antiretroviral therapy (LA-ART) with cabotegravir-rilpivirine (CAB-RPV) is approved for PWH with viral suppression on oral ART. A recent pilot project showed that monthly CAB-RPV with wrap-around social services (WS) resulted in viral suppression in most PWH who had remained viremic despite prescribed oral ART. We projected the clinical impact of providing LA-ART…

HIGH VIROLOGIC SUPPRESSION RATES ON LONG-ACTING ART IN A SAFETY-NET CLINIC POPULATION

Background: Long-acting antiretroviral therapy (LA-ART) with cabotegravir (CAB) and rilpivirine (RPV) was recently approved in the U.S., but real-world data from demonstration projects are lacking. LA-ART was approved for treatment naïve or experienced patients with virologic suppression (VS) on oral ART for at least 5 months prior to switching to injectables. However, patients with adherence…

(NEURO)INFLAMMATORY BIOMARKERS MEDIATE THE ASSOCIATION BETWEEN HIV AND DEPRESSION

Background: People with HIV are at increased risk for depression, though the underlying mechanisms for this are unclear. In the general population, depression is associated with peripheral and central inflammation. Since HIV infection may elicit (neuro)inflammation, we hypothesised that (neuro)inflammatory biomarkers would mediate the association between HIV and depression. Methods: People with and without HIV…

A NOT-SO-STABLE RESERVOIR: HIV DRIVES INFECTED CELLS TO DIE AND DIVIDE

Background: There is emerging evidence that a significant fraction of HIV proviruses on ART are transcriptionally active resulting in positive and negative selection of infected cells. Evidence of negative selection includes faster decay of intact over defective proviruses while the presence of large proviral clones with integration sites in cancer-related genes is consistent with positive…

EFFECT OF COMMON ANTIRETROVIRAL COMBINATIONS ON DEPRESSIVE SYMPTOMS IN WOMEN WITH HIV

Background: While modern antiretroviral therapy (ART) effectively suppresses HIV replication, it has been associated with neuropsychiatric adverse events including depression. We examined the combined effect of ART regimens on somatic (e.g. sleep/appetite disturbances) and non-somatic (e.g. sadness) depressive symptoms in women with HIV. Methods: Women’s Interagency HIV Study (WIHS) participants with ≥2 study visits after…

BIOPSYCHOSOCIAL PHENOTYPES IN PEOPLE WITH HIV IN THE CHARTER COHORT

Background: Neuropsychiatric complications such as neurocognitive (NC) impairment (NCI) and depression are common in people with HIV (PWH) despite viral suppression on antiretroviral therapy (ART), but these conditions are heterogeneous in their clinical presentations and associated disability. Identifying novel biopsychosocial (BPS) phenotypes that account for NC performance, depressive symptoms, and daily functioning will promote better…